BGM Group Ltd Overview

BGM Group Ltd, known as Qilian International Holding Group Ltd., operates within the health care sector, focusing on the research, development, and production of a diverse range of products. These include licorice and oxytetracycline products, medicine derivatives, sausage casings, and fertilizers. The company has established a global presence, serving customers worldwide.

Financial Snapshot

As of May 22, 2025, BGM Group Ltd’s stock closed at $14.66 on the Nasdaq exchange. The company’s market capitalization stands at approximately $1.87 billion. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $14.78 on January 7, 2025, and a low of $2.80 on June 26, 2024. The price-to-earnings ratio is currently at -65.39, indicating challenges in profitability.

Market Presence

BGM Group Ltd is listed on the Nasdaq, providing investors with access to its financial performance and strategic developments. The company maintains transparency through its investor relations website, accessible at ir.qlsyy.net.

Product Focus

The company’s product portfolio is diverse, spanning from health care products like licorice and oxytetracycline to non-health related items such as sausage casings and fertilizers. This diversification reflects BGM Group Ltd’s strategy to leverage its expertise across different markets.

Global Reach

With a commitment to serving a global customer base, BGM Group Ltd continues to expand its reach and influence in the health care sector and beyond. The company’s strategic initiatives aim to enhance its product offerings and market presence.

For further information, stakeholders and interested parties can visit the company’s investor relations website or monitor its performance on the Nasdaq exchange.